AR042651A1 - Derivados de 1-piperidin - 4- il- 4- pirrolidin -3- il- piperazina sustituidos y su uso como antagonistas de neuroquininas - Google Patents
Derivados de 1-piperidin - 4- il- 4- pirrolidin -3- il- piperazina sustituidos y su uso como antagonistas de neuroquininasInfo
- Publication number
- AR042651A1 AR042651A1 ARP030104776A ARP030104776A AR042651A1 AR 042651 A1 AR042651 A1 AR 042651A1 AR P030104776 A ARP030104776 A AR P030104776A AR P030104776 A ARP030104776 A AR P030104776A AR 042651 A1 AR042651 A1 AR 042651A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- disorders
- amino
- group
- mono
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente se refiere a derivados de 1-piperidin-4-il-pirrolidin-3-il-piperazina que tienen una actividad antagonista de neuroquinina, en particular actividad antagonista de NK1, una actividad antagonista de NK1/NK3 combinada y una actividad antagonista de NK1/NK2/NK3 combinada, su preparación, las composiciones que los comprenden y su uso en forma de medicamento, en particular para el tratamiento de la esquizofrenia, ansiedad, depresión, emesis y SII. En vista de su capacidad para antagonizar las acciones de las taquininas bloqueando los receptores de neuroquinina, y en particular antagonizando las acciones de la sustancia P y la Neuroquinina B bloqueando los receptores de NK1, NK2 y NK3, los compuestos de acuerdo con la presente son útiles como medicamento, en particular en el tratamiento profiláctico y terapéutico de las enfermedades mediadas por taquininas, tales como, por ejemplo trastornos del SNC, en particular trastornos esquizoafectivos, depresión, trastornos de ansiedad, trastornos relacionados con el estrés, trastornos del sueno, trastornos cognitivos, trastornos de personalidad, trastornos de alimentación, enfermedades neurodegenerativas, trastornos de adicción, trastornos del humor, disfunción sexual, dolor y otras enfermedades relacionadas con el SNC; inflamación, trastornos alérgicos, emesis, trastornos gastrointestinales, en particular síndrome el intestino irritable (SII); trastornos de piel, enfermedades vasoespásticas, enfermedades fibrosantes y colagenosis; enfermedades relacionadas con la intensificación o supresión inmune y enfermedades reumáticas y control del peso corporal. Reivindicación 1: Un compuesto de acuerdo con la fórmula general (1) las sales de adición con ácidos o bases farmacéuticamente aceptables de los mismos, sus formas estereoquímicamente isoméricas, su forma N-óxido y sus pro-fármacos en donde: n es un número entero, igual a 0, 1, o 2; m es un número entero, igual a 1 o 2, siempre que si m es 2, entonces n es 1; p es un número entero igual a 1 o 2; q es un número entero igual a 0 o 1; Q es O o NR3; X es un enlace covalente o un radical bivalente de fórmula -O-, -S- o -NR3-; cada R3 independientemente uno de otro, es H o alquilo; Cada R1 independientemente uno de otro, se selecciona el grupo de Ar1, Ar1-alquilo y di(Ar1)-alquilo; R2 es Ar2, Ar2-alquilo, di(Ar2)-alquilo, Het1 o Het1-alquilo; Y es un enlace covalente o u radical bivalente de fórmula -C(=O)-SO2 >C=CH-R o >C=N-R, en donde R es H, CN o nitro; cada Alq representa independientemente uno de otro, un enlace covalente, un radical hidrocarbonado bivalente recto o ramificado, saturado o no saturado que tiene de 1 a 6 átomos de carbono; o un radical hidrocarbonado cíclico saturado o no saturado que tiene de 3 a 6 átomos de C; cada radical sustituido opcionalmente sobre uno o más átomos de C con uno o más radicales fenilo, halo, ciano, hidroxi, formilo y amino; L se selecciona del grupo de H, alquilo, alquiloxi, alquiloxialquiloxi, alquilcarboniloxi, alquiloxicarbonilo, mono- y di(alquil)amino, mono y di(alquiloxicarbonil)amino, mono- y di(alquilcarbonil)amino, mono- y di(Ar3)amino, mono- y di(Ar3alquil)amino, mono- y di(Het2)amino, mono- y di(Het2alquil)amino, alquilsulfanilo, admantilo, Ar3, Ar3-oxi, Ar3carbonilo, Het2, Het-oxi y Het2carbonilo; Ar1 es fenilo, opcionalmente sustituido con 1, 2, o 3 sustituyentes, cada uno de ellos independientemente uno de otro, seleccionado del grupo de halo, alquilo, ciano, aminocarbonilo i alquiloxi; Ar2 es naftileno o fenilo, cada uno de ellos opcionalmente sustituido con 1, 2, o 3 sustituyentes, independientemente uno de otro, seleccionado del grupo de halo, nitro, amino, mono- y di(alquil)amino, ciano, alquilo, hidroxi, alquiloxi, carboxilo, alquiloxicarbonilo aminocarbonilo y mono- y di(alquil)aminocarbonilo; Ar3 es naftileno o fenilo, opcionalmente sustituido con 1, 2 o 3 sustituyentes cada uno de ellos independientemente uno de otro, seleccionado del grupo de alquiloxi, Ar1carboniloxialquio, Ar1alquiloxicarbonilo, Ar1alquiloxialquilo, alquilo, halo, hidroxi, piridinilo, morfolinilo, pirrolidinilo, imidazo[1,2-a]piridinilo, morfonilcarbonilo, pirrolidinilcarbonilo, amino y ciano; Het1 es un radical heterocíclico monocíclico seleccionado del grupo de pirrolilo, pirazolilo, imidazolilo, furanilo, tienilo, oxazolilo, isoxazolilo, tiazolilo, isotiazolilo, piridinilo, pirimidinilo, pirazinilo, y piridazinilo; o un radical heterocíclico bicíclico seleccionado del grupo de quinolinilo, quinoxalinilo, indolilo, bencimidazolilo,benzoxazolilo, bencisoxazolilo, benzotiazolilo, bencisotiazolilo, benzofuranilo, benzotienilo, indanilo y cromenilo; cada radical heterocíclico puede estar opcionalmente sustituido sobre cualquier átomo con uno o más radicales seleccionados del grupo de halo, oxo y alquilo; Het2 es un radical heterocíclico monocíclico seleccionado del grupo de pirrolidinilo, piperazinilo, imidazolidinilo, tetrahidrofuranilo, 2H-pirrolilo, pirrolinilo, imidazolidinilo, pirazolinilo, pirrolilo, imidazolilo, pirazolilo, triazolilo, furanilo, tienilo, oxazolilo, dioxazolilo, oxazolidinilo, isoxazolilo, tiazolilo, tiadiazolilo, isotiazolilo, piridinilo, pirimidinilo, pirazinilo, piridazinilo y triazinilo; o un radical heterocíclico bicíclico seleccionado del grupo de 2,3-dihidro-benzo[1,4]dioxina, octahidro-benzo[1,4]dioxina, benzopiperidinilo, quinolinilo, quinoxalinilo, indolilo, isoindolilo, cromanilo, benzoimidazolilo, imidazo[1,2-a]piridinilo, benzoxazolilo, benzoisoxazolilo, benzotiazolilo, benzoisotiazolilo, benzofuranilo y benzotienilo; o un radical tricíclico heterocíclico 8,9-dihidro-4H-1-oxa-3,5,7a-triaza-ciclopenta[f]azulenilo; cada radical puede estar opcionalmente sustituido con uno o más radicales seleccionados del grupo de Ar1, Ar1alquilo, Ar1alquiloxialquilo, halo, hidroxi, alquilo, piperidinilo, pirrolilo, tienilo, oxo, alquiloxi, alquilcarbonilo, Ar1carbonilo, mono- y di(alquil)aminoalquilo, alquiloxialquilo y alquiloxicarbonilo; y alquilo es un radical hidrocarbonado saturado recto o ramificado que tiene de 1 a 6 átomos de C o un radical hidrocarbonado cíclico saturado que tiene de 3 a 6 átomos de C; opcionalmente sustituido sobre uno o más átomos de C con uno o más radicales del grupo de fenilo, halo, ciano, oxo, hidroxi, formilo y amino.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP0214831 | 2002-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR042651A1 true AR042651A1 (es) | 2005-06-29 |
Family
ID=32668698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030104776A AR042651A1 (es) | 2002-12-23 | 2003-12-22 | Derivados de 1-piperidin - 4- il- 4- pirrolidin -3- il- piperazina sustituidos y su uso como antagonistas de neuroquininas |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US7795261B2 (es) |
| EP (1) | EP1581518B1 (es) |
| JP (1) | JP4746878B2 (es) |
| KR (1) | KR101049073B1 (es) |
| CN (1) | CN100586945C (es) |
| AR (1) | AR042651A1 (es) |
| AT (1) | ATE500242T1 (es) |
| AU (1) | AU2003302488B2 (es) |
| BR (1) | BR0317658A (es) |
| CA (1) | CA2508657C (es) |
| CL (1) | CL2003002725A1 (es) |
| CY (1) | CY1112601T1 (es) |
| DE (1) | DE60336266D1 (es) |
| DK (1) | DK1581518T3 (es) |
| EA (1) | EA009078B1 (es) |
| ES (1) | ES2361161T3 (es) |
| HK (1) | HK1087703A1 (es) |
| HR (1) | HRP20050556B1 (es) |
| IL (1) | IL169336A (es) |
| JO (1) | JO2696B1 (es) |
| MX (1) | MXPA05006887A (es) |
| MY (1) | MY145135A (es) |
| NO (1) | NO331174B1 (es) |
| NZ (1) | NZ541035A (es) |
| PA (1) | PA8593301A1 (es) |
| PL (1) | PL376048A1 (es) |
| PT (1) | PT1581518E (es) |
| SI (1) | SI1581518T1 (es) |
| TW (1) | TWI329109B (es) |
| UA (1) | UA80584C2 (es) |
| WO (1) | WO2004056799A2 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2847160A1 (fr) * | 2002-11-20 | 2004-05-21 | Oreal | Composition capillaire contenant un compose pyrasol-carboxamide, son utilisation pour stimuler la pousse des cheveux et/ou freiner leur chute |
| EA015517B1 (ru) | 2004-04-13 | 2011-08-30 | Инсайт Корпорейшн | Производные пиперазинилпиперидина в качестве антагонистов хемокинового рецептора |
| WO2005123081A2 (en) * | 2004-06-22 | 2005-12-29 | Janssen Pharmaceutica N.V. | (2-benzyl-4-{4-[1-(tetrahydrofuran-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-trifluoromethyl-phenyl))-methanone for the treatment of schizophrenia |
| WO2006071958A1 (en) * | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| WO2006071875A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| NZ556628A (en) | 2005-03-08 | 2009-09-25 | Janssen Pharmaceutica Nv | Diaza-spiro-[4.4]-nonane derivatives as neurokinin (NK1) antagonists |
| DE102005038947A1 (de) * | 2005-05-18 | 2006-11-30 | Grünenthal GmbH | Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln |
| US8754107B2 (en) * | 2006-11-17 | 2014-06-17 | Abbvie Inc. | Aminopyrrolidines as chemokine receptor antagonists |
| MX2009010499A (es) * | 2007-03-31 | 2009-10-19 | Intervet Int Bv | Procesos para elaborar zilpaterol y sales del mismo. |
| RU2442786C2 (ru) * | 2007-03-31 | 2012-02-20 | Интервет Интернэшнл Б.В. | Способы получения зилпатерола и его солей |
| HUE029053T2 (en) * | 2007-03-31 | 2017-01-30 | Intervet Int Bv | Process for the preparation of zilpaterol and its salts |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| JP5546451B2 (ja) | 2007-06-04 | 2014-07-09 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト |
| CA2689560A1 (en) * | 2007-06-07 | 2008-12-11 | F.Hoffmann-La Roche Ag | Prolinamide derivatives as nk3 antagonists |
| EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| US8507535B2 (en) * | 2010-07-07 | 2013-08-13 | Hoffmann-La Roche Inc. | Methyl-pyrrolidine ether derivatives |
| KR20150046259A (ko) * | 2012-08-23 | 2015-04-29 | 앨리오스 바이오파마 인크. | 파라믹소바이러스 바이러스성 감염의 치료용 화합물 |
| JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
| EP2968439A2 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| BR112017024852B1 (pt) | 2015-05-18 | 2023-10-31 | KaNDy Therapeutics Limited | Usos de um composto antagonista do receptor nk-1/nk-3 duplo e de uma composição farmacêutica compreendendo dito composto para o tratamento de sintomas vasomotores associados com menopausa |
| EA202092131A1 (ru) | 2018-03-14 | 2020-11-27 | Кэнди Терапьютикс Лимитед | Новый фармацевтический препарат, содержащий двойные антагонисты рецептора nk-1/nk-3 |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY110227A (en) | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
| NZ321575A (en) | 1995-10-30 | 1999-05-28 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives |
| TW382017B (en) | 1995-12-27 | 2000-02-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives |
| WO2001030348A1 (en) | 1999-10-25 | 2001-05-03 | Janssen Pharmaceutica N.V. | Use of substance p antagonists for influencing the circadian timing system |
| GB0025354D0 (en) * | 2000-10-17 | 2000-11-29 | Glaxo Group Ltd | Chemical compounds |
| US6642226B2 (en) * | 2001-02-06 | 2003-11-04 | Hoffman-La Roche Inc. | Substituted phenyl-piperidine methanone compounds |
| FR2820426B1 (fr) * | 2001-02-07 | 2007-05-11 | Condat Sa | Gel d'isolation thermique a reticulation controlee pour les lignes de transport d'hydrocarbures petroliers |
| MY141736A (en) | 2002-10-08 | 2010-06-15 | Elanco Animal Health Ireland | Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists |
-
2003
- 2003-12-15 JO JO2003174A patent/JO2696B1/en active
- 2003-12-17 ES ES03810849T patent/ES2361161T3/es not_active Expired - Lifetime
- 2003-12-17 UA UAA200505412A patent/UA80584C2/uk unknown
- 2003-12-17 KR KR1020057009197A patent/KR101049073B1/ko not_active IP Right Cessation
- 2003-12-17 DE DE60336266T patent/DE60336266D1/de not_active Expired - Lifetime
- 2003-12-17 NZ NZ541035A patent/NZ541035A/en not_active IP Right Cessation
- 2003-12-17 AU AU2003302488A patent/AU2003302488B2/en not_active Ceased
- 2003-12-17 DK DK03810849.4T patent/DK1581518T3/da active
- 2003-12-17 EA EA200501041A patent/EA009078B1/ru not_active IP Right Cessation
- 2003-12-17 EP EP03810849A patent/EP1581518B1/en not_active Expired - Lifetime
- 2003-12-17 CN CN200380106356A patent/CN100586945C/zh not_active Expired - Fee Related
- 2003-12-17 PT PT03810849T patent/PT1581518E/pt unknown
- 2003-12-17 AT AT03810849T patent/ATE500242T1/de active
- 2003-12-17 MX MXPA05006887A patent/MXPA05006887A/es active IP Right Grant
- 2003-12-17 US US10/540,447 patent/US7795261B2/en not_active Expired - Fee Related
- 2003-12-17 BR BR0317658-4A patent/BR0317658A/pt not_active IP Right Cessation
- 2003-12-17 WO PCT/EP2003/051041 patent/WO2004056799A2/en active Application Filing
- 2003-12-17 SI SI200331992T patent/SI1581518T1/sl unknown
- 2003-12-17 CA CA2508657A patent/CA2508657C/en not_active Expired - Fee Related
- 2003-12-17 PL PL03376048A patent/PL376048A1/xx not_active Application Discontinuation
- 2003-12-17 JP JP2004561504A patent/JP4746878B2/ja not_active Expired - Fee Related
- 2003-12-19 PA PA20038593301A patent/PA8593301A1/es unknown
- 2003-12-19 MY MYPI20034909A patent/MY145135A/en unknown
- 2003-12-22 TW TW092136343A patent/TWI329109B/zh not_active IP Right Cessation
- 2003-12-22 AR ARP030104776A patent/AR042651A1/es unknown
- 2003-12-22 CL CL200302725A patent/CL2003002725A1/es unknown
-
2005
- 2005-06-15 HR HRP20050556AA patent/HRP20050556B1/hr not_active IP Right Cessation
- 2005-06-22 IL IL169336A patent/IL169336A/en not_active IP Right Cessation
- 2005-07-21 NO NO20053569A patent/NO331174B1/no not_active IP Right Cessation
-
2006
- 2006-07-14 HK HK06107904.4A patent/HK1087703A1/xx not_active IP Right Cessation
-
2011
- 2011-06-01 CY CY20111100532T patent/CY1112601T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR042651A1 (es) | Derivados de 1-piperidin - 4- il- 4- pirrolidin -3- il- piperazina sustituidos y su uso como antagonistas de neuroquininas | |
| US11932643B2 (en) | Substituted heterocyclic inhibitors of PTPN11 | |
| CA2499903A1 (en) | Substituted 1,4-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists | |
| CA2509406A1 (en) | Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists | |
| AR048521A1 (es) | Derivados sustituidos de diaza-espiro-(4.5)-decano y su uso como antagonistas de neuroquininas | |
| AR040673A1 (es) | Inhibidores micobacterianos, composicion farmaceutica y proceso de preparacion del compuesto | |
| AU2017274199A1 (en) | Heterocyclic inhibitors of PTPN11 | |
| AR035668A1 (es) | Imidazoquinolinas y 6,7,8,9-tetrahidroimidazoquinolinas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos | |
| AR053436A1 (es) | Iderivados de 3-(indazol-5-il)-(1,2,4)triazina inhibidores de quinasas | |
| CN102131807A (zh) | 吡唑并吡啶激酶抑制剂 | |
| BR112019011801A2 (pt) | composto, composição farmacêutica e método de inibição de dlk, método de tratamento de uma doença mediada por dlk, método de tratamento de câncer e redução do desenvolvimento de um distúrbio neurológico induzido por quimioterapia e método para alcançar um efeito em um paciente | |
| KR20100023040A (ko) | 폴리사이클릭 구아닌 유도체 및 이의 용도 | |
| AR054231A1 (es) | Composiciones farmaceuticas | |
| WO2018044808A1 (en) | Inhibitors of dual leucine ziper (dlk) kinase for the treatment of disease | |
| CA2561944A1 (en) | Substituted diaza-spiro-[5.5]-undecane derivatives and their use as neurokinin antagonists | |
| AR045913A1 (es) | Derivados olefinicos de 8-azabiciclo[3,2,1]octanos como antagonistas de receptores muscarinicos de acetilcolina | |
| AR042653A1 (es) | Derivados sustiuidos de 1- piperidin -3- il- 4- piperidin 4- -il- piperazina y su uso como antagonistas de taquiquininas | |
| AR044490A1 (es) | Formulaciones para tratamientos de base opioidea para el dolor que comprenden derivados sustituidos de 1,4 - di- piperidin - 4- il- piperazina | |
| CA2509090A1 (en) | Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists | |
| AR052342A1 (es) | Derivados sustituidos de triazolona,tetrazolona e imidazolona con actividad selectiva antagonista de alfa2c-adenoreceptores | |
| AR040974A1 (es) | Derivados heterociclicos de isoxazolina fusionados y su uso como antidepresivos | |
| CA3221771A1 (en) | Combination therapies comprising a mettl3 inhibitor and a further anticancer agent | |
| AR041020A1 (es) | Derivados de isoxazolina c6- y c9- substituidos; su uso para la manufactura de un medicamento y composicion farmaceutica | |
| WO2005087775A1 (ja) | 三環式複素環化合物およびその化合物を有効成分として含有する医薬組成物 | |
| CA3236550A1 (en) | Spirotricycle ripk1 inhibitors and methods of uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |